Jae Hoon Lee
Hematology Jae Hoon Lee Favorite Doctor
  • SpecialtyBlood cancers (leukemia, myeloma, lymphoma), blood diseases
  • Site
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM   Present     Present  
PM   Present        
Clinical Interests

Multiple myeloma
Chronic leukemia
Malignant lymphoma
Myeloproliferative neoplasm
Benign blood diseases (anemia, thrombocytopenia, aplastic anemia, blood clotting disorder)

Education
Education
1976 Jemulpo High School
1982 Seoul National University College of Medicine, MD
1985 Seoul National University Graduate College of Medicine, M.S
1991 Seoul National University Graduate College of Medicine, Ph.D.
Career
Career
1982 Seoul National University Hospital, Intern
1983 Department of Internal Medicine, Seoul National University Hospital, Rsident
1986 Department of Hematolgy Oncology, Seoul National University Hospital, Fellow
1987 Seoul National University College of Medicine, Full-time Instructor, Assistant Professor
1995 Department of Hematology Oncology, Gachon University Gil Medical Center, Head of Department
1999 Department of Internal Medicine, Gachon university Gil Medical Center, Associate Professor
1999 Head of Department of Hematology Oncology, Gachon university Gil Medical Center
2002~ Gachon Unviersity Gil Medical Center, Professor
2012 Director of Clinical Research Center, Gachon University Gil Medical Center
2019 Director of Incheon Regional Cancer Center
<Awards>
2002 Korea Society of Hematology, Achievement Award
2016 Korean Society of Hematology, Academic Award
2018 Korean Society of Blood and Marrow Transplatation, Achievement Award
More
Community
Community
More
Training
Training
University of Arkansas for Medical Science (UAMS), USA
Myeloma Research Center, Ak, USA
Charite Hospital CBF, Humboldt University, Berlin, Germany
License
License
1982 Medical License
1986 Internal Medicine Specialist
1992 Hematology Oncology Specialist
Jae Hoon Lee
Paper
Paper
2019 Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Lancet. 2019 Jan 19;393(10168):253-264.
2019 Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. Park SS, Eom HS, Kim JS, Koh Y, Choi CW, Lee JJ, Kim K, Suh C, Lee JH, Min CK; Korean Multiple Myeloma Working Party. Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177.
2019 Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Arg&uuml;elles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B. Ann Hematol. 2019 Feb 6. doi: 10.1007/s00277-019-03602-4. [Epub ahead of print]
2019 Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Blood. 2019 Feb 28
2019 Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Br J Haematol. 2019 Mar;184(5):735-743
2019 A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC, Lee JJ, Eom HS, Kim JS, Min CK; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2019 Mar 23. pii: S1083-8791(19)30192-2. doi: 10.1016/j.bbmt.2019.03.016. [Epub ahead of print]
2019 Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28
2019 Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Mac&iacute;as G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, L&oacute;pez-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6.
2019 Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6
2019 Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L&oacute;pez-Jim&eacute;nez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum in: JAMA. 2019 Aug 27;322(8):785
2019 A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC, Lee JJ, Eom HS, Kim JS, Min CK; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2019 Jul;25(7):1312-1319. doi: 10.1016/j.bbmt.2019.03.016. Epub 2019 Mar 23.
2019 Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ. Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1.
2019 Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C. Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.
2019 Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Fujisaki T, Ishikawa T, Takamatsu H, Suzuki K, Min CK, Lee JH, Wang J, Carson R, Crist W, Qi M, Nagafuji K. Ann Hematol. 2019 Oct 16. doi: 10.1007/s00277-019-03794-9. [Epub ahead of print]
2018 Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, Nawarawong W, Huang SY, Sang Chim C, Kim K, Kumar L, Malhotra P, Chng WJ, Durie B; Asian Myeloma Network. Leuk Lymphoma. 2018 Feb 2:1-13
2018 Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print]
2018 Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182
2018 Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12
2018 Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Ill&eacute;s &Aacute;, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10.
2018 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Korean J Intern Med. 2018 Jan;33(1):168-175 2018
2018 A predictive model for risk of early grade&#8201;≥&#8201;3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Math&eacute; Y, Facon T. Leukemia. 2018 Jun;32(6):1404-1413
2018 The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K. Acta Haematol. 2018 Sep 25;140(3):146-156. doi: 10.1159/000490488. [Epub ahead of print]
2018 Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.
2018 Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Br J Haematol. 2018 Dec 12. doi: 10.1111/bjh.15700. [Epub ahead of print] PMID: 30548250
2018 Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Lancet. 2018 Dec 10. pii: S0140-6736(18)33003-4. doi: 10.1016/S0140-6736(18)33003-4. [Epub ahead of print]
2017 Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Seo JY, Hong J, Chun K, Jeong J, Cho H, Kim KH, Park J, Ahn JY, Park PW, Lee JH. Leuk Lymphoma. 2017 Feb;58(2):357-365.
2017 Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the FIRST Trial. Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T. Br J Hematol 2017 Mar;176(5):743-749
2017 Deacetylase Inhibitors: an Advance in Myeloma Therapy? Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG. Expert Rev Hematol. 2017 Mar;10(3):229-
2017 Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi
2017 YS, Kim SH, Yoon SS. Cancer Med. 2017 Jan;6(1):100-108
2017 A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY. Oncotarget. 2017 Jun 6;8(23):37605-3761
2017 Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. Suh KJ, Cheong JW, Kim I, Kim HJ, Shin DY, Koh Y, Yoon SS, Min YH, Ahn JS, Kim YK, Lee YG, Lee JO, Bang SM, Mun YC, Seong CM, Park Y, Kim BS, Hong J, Park J, Lee JH, Kim SY, Lee HG. PLoS One. 2016 Nov 8;11(11):
2017 Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS working party. Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, Jo DY, Kim H, Lee H, Bang SM, Lee WS, Park Y, Lee MH, Lee JH, Bae SH, Kim MK; Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017 May 29;8(45):79414-794249. doi: 10.18632/oncotarget.18258. [Epub ahead of print]
2017 The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. Oncotarget. 2017 Jun 16;8(45):79517-79526
2017 Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG. Br J Haematol. 2017 Oct;179(1):66-74
2017 Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Leukemia. 2017 May 12. doi: 10.1038/leu.2017.138. [Epub ahead of print]
2017 Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; Korean Multiple Myeloma Working Party. Am J Hematol. 2017 Dec;92(12):1280-1286
2017 Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Blood Res. 2017 Sep;52(3):200-206
2017 Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. Choi CW, Jang JH, Kim JS, Jo DY, Lee JH, Kim SH, Kim YK, Won JH, Chung JS, Kim H, Lee JH, Kim MK, Eom HS, Hyun SY, Kim JA, Lee JW. Blood Res. 2017 Sep;52(3):207-211.
2017 Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182.
2016 Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. Hong J, Woo HS, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Support Care Cancer. 2016 Jan;24(1):187-94.
2016 Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Kim YS, Cho EK, Woo HS, Hong J, Ahn HK, Park I, Sym SJ, Kyung SY, Kang SM, Park JW, Jeong SH, Park J, Lee JH, Shin DB. Cancer Res Treat. 2016;48(1)80-87
2016 Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Blood. 2016 Feb 11;127(6):713-21
2016 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H&aacute;jek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosi&ntilde;ol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Lancet Oncol. 2016 Jan;17(1):27-38
2016 Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. N Engl J Med. 2016, 28;374(17):1621-34
2016 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Korean J Intern Med. 2016 Apr 20
2016 Prgostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy. Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Cancer Res Treat. 2016 Mar 23
2016 A successful planned pregnancy and delivery with eculizumab maintenance in a woman with Paroxysmal Nocturnal Hemoglobinuria. Eun Yeong Cho1, Ae Jin Kim1, Ji Yong Jung1, Jeong Yeal Ahn2, Suk Young Kim3, and Jae Hoon Lee. Suncheonhyang Med Science 2016; 22(1):50-53, 2016
2016 Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Jang JE, Cheong JW, Kim SJ, Cho H, Suh C, Lee H, Eom HS, Yhim HY, Lee WS, Min CK, Lee JH, Park JS, Kim JS. Leuk Lymphoma. 2016 Jun;57(6):1389-97
2016 Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Hong J, Lee S, Chun G, Jung JY, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Blood Research 2016 Jun;51(2):113-21
2016 Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Jeong JH, Lee HT, Seo JY, Seo YH, Kim KH, Kim MJ, Lee JH, Park J, Hong JS, Park PW, Ahn JY. Ann Lab Med. 2016 Jul;36(4):291-9.
2016 Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study. Byun JM, Kim YJ, Yoon HJ, Kim SY, Kim HJ, Yoon J, Min YH, Cheong JW, Park J, Lee JH, Hong DS, Park SK, Kim HJ, Ahn JS, Shin HJ, Chung JS, Lee WS, Lee SM, Park Y, Kim BS, Lee JH, Lee KH, Jung CW, Jang JH, Min WS, Park TS; AML/MDS working party of Korean Society of Hematology. Ann Hematol. 2016 Aug;95(8):1223-32
2016 Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Yoon DH, Kim SJ, Jeong SH, Shin DY, Bae SH, Hong J, Park SK, Yhim HY, Yang DH, Lee H, Kang HJ, Lee MH, Eom HS, Kwak JY, Lee JH, Suh C, Kim WS. Oncotarget. 2016 Aug 16. doi: 10.18632/oncotarget.11319. [Epub ahead of print]
2016 Recent Advances in Multiple Myeloma: a Korean Perspective. Hong J and Lee JH. Korean J Intern Med 2016 Sep;31(5):820-34
2016 Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK; Korean Multiple Myeloma Working Party. Blood Res. 2016 Sep;51(3):193-199.
2016 Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, G&uuml;nther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi: 10.1016/S2352-3026(16)30147-8
2016 Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Cancer Res Treat. 2016 Oct;48(4):1264-1273
2016 Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi YS, Kim SH, Yoon SS. Cancer Med. 2016 Dec 1. doi: 10.1002/cam4.970. [Epub ahead of print]
2016 Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. Suh KJ, Cheong JW, Kim I, Kim HJ, Shin DY, Koh Y, Yoon SS, Min YH, Ahn JS, Kim YK, Lee YG, Lee JO, Bang SM, Mun YC, Seong CM, Park Y, Kim BS, Hong J, Park J, Lee JH, Kim SY, Lee HG. PLoS One. 2016 Nov 8;11(11):e0166245. doi: 10.1371/journal.pone.0166245
2016 A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer. Sym SJ, Hong J, Jung M, Koo YS, Park YH, Kim KK, Park J, Cho EK, Lee JH, Shin D. J Clin Oncol. 2012 Feb;30(4_suppl):344.
2015 Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.Kim HJ, Yoon SS, Eom HS, Kim K, Kim JS, Lee JJ, Bang SM, Min CK, Park JS, Lee JH; Korean Multiple Myeloma Working Party.Blood Res. 2015 Mar;50(1):7-18.. Review
2015 Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Song MK, Chung JS, Lee JJ, Lee JH, Song IC, Lee SM, Shin DY, Lee GW, Lee IS. Acta Haematol. 2015;134(1):7-16
2015 Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C. Cancer Res Treat. 2015 Apr;47(2):173-81
2015 Nilotinib combined with multi-agent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH. Blood. 2015 ;126(6) : 746-56
2015 A Case of Primary Breast Diffuse Large B-Cell Lymphoma Treated with Chemotherapy Followed by Elective Field Radiation Therapy: A Brief Treatment Pattern Review from a Radiation Oncologist’s Point of View. Kyu Chan Lee, Seung Heon Lee, KiHoon Sung, So Hyun Ahn, Jinho Choi, Seok Ho Lee, Jae Hoon Lee, Junshik Hong, and Sang Hui Park. Case Reports in Oncological MedicineVolume 2015 (2015)
2015 Long-term follow-up of imatinib plus combination chemotherapy in for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lim SN, Joo YD, Lee KH, Kim DY, Lee JH, Lee JH, Chi HS, Yun SC, Lee WS, Lee SM, Park S, Kim I, Sohn SK, Moon JH, Ryoo HM, Bae SH, Hyun MS, Kim MK, Kim HJ, Yang DH, Eom HS, Lee GW, Jung CW, Won JH, Kim H, Lee JH, Shin HJ, Jang DY. Am J Hematol. 2015, Nov; 90(11): 1013-20
2015 Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.
2015 Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. Park S, Hong J, Hwang I, Ahn JY, Cho EY, Park J, Cho EK, Shin DB, Lee JH. J Geriatr Oncol. 2015 Nov;6(6):470-8.
2015 Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Kim YS, Sym SJ, Baek MY, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Cancer Chemother Pharmacol. 2015 Dec;76(6):1267-72.
2015 Successful Treatment with Low-dose Rituximab in a Patient with Plasma Exchange-refractory Idiopathic Thrombotic Thrombocytopenic Purpura. Song KH, Hong J, Hwang H, Park J, Ahn JY, Lee JH Korean J Int Med 2015;89(6):709-713
2014 A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH , Shin DB. Cancer Chemother Pharmacol. 2014 2014 Jan;73(1):163-9.
2014 High-dose Etoposide plus G-CSF as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma (CISL) Hyun SY, Cheong JW, Lim SJ, Min YH, Yang DH, Ahn JS, Ryoo HM, Do YR, Lee HS, Lee JH , Oh SY, Suh C, Yhim HY, Kim JS. Biol BMT 2014 Jan ;20(1):73-9
2014 Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Kim K, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH , Min CK; Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2014 Jan ;93(1):113-121]
2014 Acute myeloid leukemia with persistent marrow aplasia after chemotherapy treated with reduced intensity allo-stem cell transplantation. Yoon H, Hong J, Kim S, Lee DM, Park J, Ahn JY, Lee JH. KJIM 2013;86(2):242-6
2014 IMWG consensus on risk stratification in multiple myeloma. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. Leukemia. 2014 Feb;28(2):269-77
2014 Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Tumour Biol. 2014 Jun;35(6):5735-40.
2014 Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Yi HG, Lee MH, Kim CS, Hong J, Park J, Lee JH, Han BR, Kim HY, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY, Gyeonggi/Incheon Branch, The Korean Society of Hematology. Blood Res. 2014 Jun;49(2):95-99.
2014 Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH , Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party. Transfusion. 2014 June;54(6):1542-51
2014 Clinical profiles of multiple myeloma in Asia - an Asian Myeloma Network (AMN) study. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim J, Nawarawong W, Siritanaratkul N, Durie BG. Am J Hematol. 2014 Jul;89(7):751-6.
2014 Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim CS, Mun YC, Kim, Lee DS, Lee JH. ; the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol 2014 Aug;93(8):1353-61.
2014 Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients. Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; The Korean Society of Hematology AML/MDS Working Party. Int J Hematol. 2014 Aug;100(2):141-51
2014 Prognostic Value of Metabolic Tumor Volume Estimated by 18F-FDG Positron Emission Tomography/Computed Tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Nuclear Medicine and Molecular Imaging 2014 Sep;48(3):187-95.
2014 Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal
More